Eisai and Biogen Alzheimer's drug lecanemab receives approval from FDA
Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.
Stay updated with breaking news from Ivan Cheung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.
CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.
LOS ANGELES (Reuters) -Eisai and Biogen's Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer's treatment to achieve that goal, clearing the way for wider insurance coverage of the drug. The FDA decision marks a new milestone for a fatal disease that has eluded drugmakers' efforts for decades. Trial data showed that the treatment slows progression of the brain-wasting disease by 27% for patients in the earliest stages of Alzheimer's.
Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.
A new milestone for a fatal disease that has eluded drugmakers' efforts for decades.